{"filing":{"accession_number":"0001193125-26-391903","cik":"0001544227","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-11","primary_document":"d108044d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526391903/d108044d8k.htm"},"events":[{"id":33611,"run_id":30913,"accession_number":"0001193125-26-391903","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Tempest Therapeutics entered into a securities purchase agreement on September 11, 2026, for a private placement of pre-funded warrants and common warrants to purchase up to 3,105,591 shares of common stock, generating approximately $2.5 million in gross proceeds with up to ~$5 million in additional proceeds upon warrant exercise. The unregistered offering was conducted under Section 4(a)(2) and Regulation D exemptions and includes lock-up restrictions and registration obligations.","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":37102,"accession_number":"0001193125-26-391903","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Tempest Therapeutics entered into a securities purchase agreement on September 11, 2026, for a private placement of pre-funded warrants and common warrants to purchase up to 3,105,591 shares of common stock, generating approximately $2.5 million in gross proceeds. The filing discloses a dilutive equity issuance with significant warrant coverage (up to ~$5 million additional proceeds upon exercise), lock-up restrictions, and registration obligations—hallmarks of a PIPE-like private placement that materially dilutes existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:09:04.827922+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37103,"accession_number":"0001193125-26-391903","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered private placement of equity securities by Tempest Therapeutics exempt under Section 4(a)(2) and Regulation D. The filing explicitly references securities \"offered and sold in a private placement\" and incorporates details from Item 1.01, indicating a material capital raise through dilutive equity issuance typical of small-cap biotech companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:09:04.827922+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37102,"accession_number":"0001193125-26-391903","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Tempest Therapeutics entered into a securities purchase agreement on September 11, 2026, for a private placement of pre-funded warrants and common warrants to purchase up to 3,105,591 shares of common stock, generating approximately $2.5 million in gross proceeds. The filing discloses a dilutive equity issuance with significant warrant coverage (up to ~$5 million additional proceeds upon exercise), lock-up restrictions, and registration obligations—hallmarks of a PIPE-like private placement that materially dilutes existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:09:04.827922+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-09-15"},{"id":37103,"accession_number":"0001193125-26-391903","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered private placement of equity securities by Tempest Therapeutics exempt under Section 4(a)(2) and Regulation D. The filing explicitly references securities \"offered and sold in a private placement\" and incorporates details from Item 1.01, indicating a material capital raise through dilutive equity issuance typical of small-cap biotech companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:09:04.827922+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-09-15"}]}